Romana Hochreiter
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.
A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.
Journal: Nature communications
Published: April 14, 2026
Protective properties of a candidate C-terminal domain OspA vaccine for prevention of Lyme disease.
Journal: Vaccine
Published: September 02, 2025
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.
Journal: Nature medicine
Published: July 07, 2025
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil.
Journal: The Lancet. Infectious diseases
Published: June 02, 2025
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: April 01, 2025
Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.
Journal: Emerging microbes & infections
Published: February 25, 2025
Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: October 21, 2024
From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.
Journal: Journal of travel medicine
Published: June 30, 2024
Preclinical Evidence for the Protective Capacity of Antibodies Induced by Lyme Vaccine Candidate VLA15 in People.
Journal: Open forum infectious diseases
Published: May 21, 2024
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.
Journal: The Lancet. Infectious diseases
Published: May 16, 2024
Last Updated: 09/26/2026